Metastatic Squamous Cell Carcinoma Neck Clinical Trial
Official title:
An Exploratory Tumor Biopsy-Driven Study to Understand the Relationship Between Biomarkers and Clinical Response in Immunomodulatory Treatment-Naïve Patients With Recurrent and/or Metastatic Squamous Cell Carcinoma of Head and Neck Receiving REGN2810 (Anti-PD-1)
| Verified date | March 2020 |
| Source | Regeneron Pharmaceuticals |
| Contact | n/a |
| Is FDA regulated | No |
| Health authority | |
| Study type | Interventional |
This study is being conducted to compare the relationship of patient response to treatment to changes in tumor microenvironment.
| Status | Completed |
| Enrollment | 33 |
| Est. completion date | February 21, 2020 |
| Est. primary completion date | June 27, 2019 |
| Accepts healthy volunteers | No |
| Gender | All |
| Age group | 18 Years and older |
| Eligibility |
Key Inclusion Criteria: 1. Histologically confirmed diagnosis of recurrent and/or metastatic SCCHN (squamous cell carcinoma of the head and neck) with no curative options with at least 1 lesion that is measurable by Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 criteria and accessible for biopsies. Primary tumor sites of oral cavity, oropharynx, larynx, or hypopharynx are included. 2. Have failed/are refractory to at least first line chemotherapy OR deemed unsuitable candidate for first line chemotherapy due to medical co-morbidities or patient preference 3. Eastern Cooperative Oncology Group (ECOG) performance status (PS) of 0 or 1 4. Adequate hepatic function 5. Adequate renal function 6. Adequate bone marrow function 7. Provide signed informed consent 8. Willing and able to comply with clinic visits and study-related procedures Key Exclusion Criteria: 1. Ongoing or recent (within 5 years) evidence of significant autoimmune disease that required treatment with systemic immunosuppressive treatments, which may suggest risk for immune-related adverse event (irAEs) 2. Prior treatment with an agent that blocks the programmed death-1/programmed death-ligand 1 (PD-1/PD-L1) pathway 3. Prior treatment with other immune modulating anti-cancer agents 4. Untreated or active brain metastases or spinal cord compression 5. Immunosuppressive corticosteroid doses within 4 weeks prior to the first dose of REGN2810 6. Prior treatment with idelalisib Other protocol-defined inclusion/exclusion criteria will apply |
| Country | Name | City | State |
|---|---|---|---|
| Korea, Republic of | Samsung Medical Center | Seoul | |
| Korea, Republic of | Seoul National University | Seoul | |
| Korea, Republic of | Yonsei University College of Medicine, Severence Hospital | Seoul | |
| United Kingdom | University Birmingham | Birmingham | |
| United Kingdom | Guy's and St. Thomas' NHS Foundation Trust | London | |
| United Kingdom | Royal Cancer Hospital | London |
| Lead Sponsor | Collaborator |
|---|---|
| Regeneron Pharmaceuticals | Sanofi |
Korea, Republic of, United Kingdom,
| Type | Measure | Description | Time frame | Safety issue |
|---|---|---|---|---|
| Primary | Correlation between changes in the tumor microenvironment and the change in tumor volume following REGN2810 treatment versus baseline. | At baseline and during REGN2810 treatment up to week 24 | ||
| Secondary | Correlation between baseline tumor characteristics and the change in tumor volume following REGN2810 treatment | At baseline and during REGN2810 treatment up to week 24 | ||
| Secondary | Number of participants with treatment-related adverse events | Up to 54 weeks | ||
| Secondary | Concentrations of REGN2810 in serum | Up to 54 weeks | ||
| Secondary | Anti-REGN2810 antibody levels | Up to 54 weeks | ||
| Secondary | The overall response rate (ORR) in patients treated with REGN2810 | Up to 54 weeks | ||
| Secondary | The progression-free survival (PFS) in patients treated with REGN2810 | Up to 54 weeks |